1. INTRODUCTION {#sec1}
===============

Despite advancements in the delivery of ophthalmological care, diabetic retinopathy remains a major cause of preventable blindness \[[@B1]\]. The two most important visual complications of diabetic retinopathy are diabetic macular edema (DME) and proliferative diabetic retinopathy (PDR). Glycemic control \[[@B2], [@B3]\] and photocoagulation \[[@B4], [@B5]\] have been standard treatments for both DME and PDR for over 3 decades. Nevertheless, some patients suffer permanent visual loss despite prompt and appropriate therapy.

In recent years, further advances in pharmacotherapy have shown promise in the treatment of diabetic retinopathy. The three major classes of medications currently being studied are corticosteroids, vascular endothelial growth factor (VEGF) antagonists, and miscellaneous agents. Multiple clinical series have been reported ([Table 1](#T1){ref-type="table"}), and many more are ongoing or being planned ([Table 2](#T2){ref-type="table"}).

2. CORTICOSTEROIDS {#sec2}
==================

Corticosteroids may work through multiple mechanisms of action. In addition to their well-known anti-inflammatory effects, corticosteroids may cause downregulation of VEGF \[[@B6], [@B7]\]. Intravitreal triamcinolone acetonide (IVTA) is commonly used today as an off-label adjunctive treatment of DME ([Figure 1](#F1){ref-type="fig"}). Other intravitreal corticosteroids under study include a sustained-release device containing fluocinolone acetonide (Retisert; Bausch & Lomb, Rochester, NY) and extended-release dexamethasone in a biodegradable polymer (Posurdex, Allergan, Irvine, Calif).

2.1. Triamcinolone acetonide {#subsec2.1}
----------------------------

Although intravitreal triamcinolone acetonide (Kenalog 40, Bristol-Myers Squibb, Princeton, NJ) has been administered for many years \[[@B8]\], its use has become more common since 2002 \[[@B9]--[@B11]\]. Recent prospective, randomized clinical trials have demonstrated generally favorable outcomes \[[@B12], [@B13]\]. The Diabetic Retinopathy Clinical Research network (DRCR.net) has completed enrollment on a three-year, randomized, prospective, multicenter clinical trial comparing two doses (1 mg and 4 mg) of preservative-free IVTA (Allergan, Irvine, Calif) with modified early treatment diabetic retinopathy study (ETDRS) photocoagulation for DME. Furthermore, IVTA may be a useful adjunct to photocoagulation for PDR, perhaps by decreasing the macular edema sometimes worsened by the treatment \[[@B14], [@B15]\].

The most important complication of IVTA is increased intraocular pressure (IOP) resulting in secondary open-angle glaucoma, which sometimes may be severe \[[@B16]\] and intractable \[[@B17], [@B18]\]. Elevation of IOP up to 24 mm Hg may occur in about 40% of patients, usually within about 3 months \[[@B19]\]. The second most important complication of IVTA is cataract formation, which may become visually significant in about half of eyes within 1 year \[[@B20]\].

The rates of injection-related endophthalmitis following IVTA have been reported to be in the range of 0.099%--0.87% per injection \[[@B21], [@B22]\]. The incidence of pseudoendophthalmitis, due to migration of triamcinolone acetonide crystals into the anterior chamber, is probably higher than that of infectious endophthalmitis. Other reported complications of IVTA (and of any intravitreal injection) include retinal detachment, lens trauma, and vitreous hemorrhage.

The use of peribulbar, rather than intravitreal, triamcinolone acetonide offers reduced risks of endophthalmitis and perhaps other complications. Peribulbar triamcinolone acetonide may have some limited efficacy for patients with DME \[[@B23], [@B24]\] although the bulk of the current literature appears to indicate that IVTA is more effective \[[@B25], [@B26]\]. DRCR.net has recently published a phase 2 randomized, prospective, multicenter clinical trial comparing peribulbar triamcinolone acetonide with and without photocoagulation. Peribulbar triamcinolone did not significantly improve vision in patients with mild DME \[[@B48]\]. Neither peribulbar triamcinolone nor IVTA appears to offer long-term efficacy for DME, which has led to the investigation of various extended-release corticosteroids.

2.2. Fluocinolone acetonide {#subsec2.2}
---------------------------

The fluocinolone acetonide intravitreal implant (Retisert) is FDA-approved for the treatment of chronic, noninfectious posterior segment uveitis \[[@B27]\]. Although the device was also studied in patients with DME, no specific results has been published in the peer-reviewed literature at this time \[[@B28]\].

2.3. Extended-release dexamethasone {#subsec2.3}
-----------------------------------

A bioerodable, extended-release dexamethasone implant (Posurdex, Allergan, Irvine, Calif) has shown favorable outcomes in the treatment of macular edema due to various etiologies, including DME, in a recent phase 2 study \[[@B29]\]. A phase 3 trial is underway.

3. VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) INHIBITORS {#sec3}
=======================================================

Vascular endothelial growth factor (VEGF) increases retinal vascular permeability, causes breakdown of the blood-retinal barrier, and results in retinal edema \[[@B30]\]. VEGF is upregulated in diabetic retinopathy \[[@B31]\] and is present in increased levels in the aqueous and vitreous humor of patients with PDR \[[@B32], [@B33]\]. At least 5 isoforms of VEGF are known \[[@B34]\]. Three currently available anti-VEGF agents are pegaptanib, bevacizumab, and ranibizumab.

3.1. Pegaptanib {#subsec3.1}
---------------

Pegaptanib (Macugen, OSI/Eyetech, Melville, NY) is a pegylated aptamer directed against the VEGF-A 165 isoform. It was the first FDA-approved ophthalmologic anti-VEGF agent, for the treatment of choroidal neovascularization from age-related macular degeneration (AMD) \[[@B35]\]. In a phase 2, prospective clinical trial, pegaptanib appeared to improve anatomic and visual outcomes in patients with DME \[[@B36]\]. Retrospective analysis of these data demonstrated some efficacy on retinal neovascularization as well \[[@B37]\]. Phase 3 trials of pegaptanib for DME are currently being conducted.

3.2. Bevacizumab {#subsec3.2}
----------------

Bevacizumab (Avastin, Genentech, Inc., South San Francisco, Calif), a full-length recombinant humanized antibody, is active against all isoforms of VEGF-A. It is FDA-approved as an adjunctive systemic treatment for metastatic colorectal cancer \[[@B49]\]. Although off-label systemic bevacizumab has demonstrated some efficacy for exudative AMD \[[@B50]\], the agent has shown greater promise as an intravitreal medication. Case reports and small observational series have been reported using off-label intravitreal bevacizumab to treat exudative AMD \[[@B51]\], macular edema from nonischemic central retinal vein occlusion \[[@B52]\], iris neovascularization \[[@B53], [@B54]\], pseudophakic cystoid macular edema \[[@B55]\], and other diseases. Small, nonrandomized pilot studies have documented some efficacy against diffuse DME \[[@B56]\] and various complications of PDR \[[@B38]--[@B40]\] ([Figure 2](#F2){ref-type="fig"}).

DRCR.net has completed enrollment on a phase 2, prospective, randomized, multicenter clinical trial to determine the safety and possible benefits of this agent. Plans for a phase 3 trial of two doses of an intravitreal anti-VEGF agent versus modified ETDRS grid laser photocoagulation for DME are under discussion.

3.3. Ranibizumab {#subsec3.3}
----------------

Ranibizumab (Lucentis, Genentech, Inc., South San Francisco, Calif), a recombinant humanized antibody fragment, is active against all isoforms of VEGF-A. Intravitreal ranibizumab is FDA-approved for the treatment of exudative AMD \[[@B57], [@B58]\]. Two pilot studies of ranibizumab demonstrated some efficacy in the treatment of DME \[[@B41], [@B42]\]. DRCR.net is planning two phase 3, prospective, randomized, multicenter trials comparing patients. In the first trial, patients with DME and no PDR will be randomized to: (1) modified ETDRS grid laser photocoagulation; (2) photocoagulation before ranibizumab; (3) photocoagulation plus IVTA; or (4) ranibizumab before photocoagulation. In the second trial, patients with DME and PDR will be randomized to: (1) modified ETDRS grid laser photocoagulation plus scatter photocoagulation; (2) modified ETDRS grid laser photocoagulation plus scatter photocoagulation plus ranibizumab; or (3) modified ETDRS grid photocoagulation plus scatter photocoagulation plus IVTA.

The risk of injection-related endophthalmitis with the anti-VEGF agents is variable, but appears to be lower in more recent studies. Major prospective clinical trials of pegaptanib and ranibizumab reported rates between 0.7%--1.6% per eye \[[@B35], [@B57]--[@B59]\]. Most eyes in these reports received a series of injections, and a recent observational case series reported an incidence of 0.014% per injection for bevacizumab \[[@B60]\].

4. OTHER AGENTS {#sec4}
===============

4.1. Ruboxistaurin {#subsec4.1}
------------------

The enzyme protein kinase C *β* (PKC *β*) is activated by VEGF and appears to increase various systemic complications, including diabetic retinopathy \[[@B61]\]. Ruboxistaurin (Arxxant, Eli Lilly and Company, Indianapolis, Ind), an orally administered PKC *β* inhibitor, has shown efficacy against DME in two separate phase 3 trials \[[@B43], [@B44]\], although a recent study reported that treatment did not delay disease progression over a 30-month followup \[[@B45]\]. A smaller study noted that ruboxistaurin treatment was associated with a reduction in retinal vascular leakage, as measured by vitreous fluorometry, but visual acuity was not affected \[[@B46]\]. Although Lilly received an approvable letter from the FDA on August 18, 2006, the FDA requested an additional, 3-year, Phase 3 clinical trial to collect additional efficacy data in spite of an appeal with additional data.

4.2. Hyaluronidase {#subsec4.2}
------------------

In an attempt at pharmacologic vitreolysis, intravitreal purified ovine hyaluronidase (Vitrase, ISTA Pharmaceuticals, Irvine, Calif) was proposed to accelerate clearance of vitreous hemorrhage from PDR and other causes. A recent phase 3 prospective clinical trial showed some favorable efficacy \[[@B47]\] and safety \[[@B62]\] outcomes for the clearance of vitreous hemorrhage due to all causes, but this agent is not currently FDA-approved for this indication.

5. CLINICAL GUIDELINES {#sec5}
======================

Although none of the pharmacologic agents discussed above is FDA-approved for treatment of patients with diabetic retinopathy, off-label treatment can be considered for patients unresponsive to traditional standard care. These guidelines are summarized in [Table 3](#T3){ref-type="table"}.

In patients with diabetic macular edema not responsive to photocoagulation, either IVTA or an intravitreal anti-VEGF agent may be considered as second-line treatments. At this time, there are no published head-to-head comparisons of IVTA versus the anti-VEGF agents for this disease, although the pending DRCR.net trials may provide useful guidelines in this regard. Triamcinolone may be relatively more efficacious for DME, while the anti-VEGF agents appear more efficacious for PDR. Triamcinolone is considerably less expensive than the anti-VEGF agents, but is associated with risks of elevated IOP, cataract, and pseudoendophthalmitis.

In patients with complications of PDR not amenable to photocoagulation, intravitreal anti-VEGF agents may produce short-term stabilization or regression of iris and/or retinal neovascularization. In most patients, however, photocoagulation will eventually be necessary.

Intravitreal anti-VEGF agents may be helpful in patients with dense vitreous hemorrhage and patients with glaucoma secondary to neovascularization. If B-scan echography shows no evidence of retinal detachment, these agents may provide useful short-term anatomic improvement, until definitive photocoagulation can be given, or to reduce intraoperative bleeding in eyes with neovascular glaucoma.

6. SUMMARY {#sec6}
==========

Clinical experience with pharmacologic treatment for diabetic retinopathy continues to increase and reported outcomes in observational case series are promising. At this time, improved metabolic control and local ocular treatments (photocoagulation and vitrectomy) remain the proven treatments, through evidence-based medicine. As prospective randomized clinical trials accumulate data, the role of pharmacologic treatments will become clearer.
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![Intravitreal triamcinolone acetonide for diabetic macular edema. A patient presented with diabetic macular edema, visual acuity 20/60. Fundus photography (a) and optical coherence tomography (OCT) (b, c) are shown. The patient was treated with intravitreal triamcinolone acetonide. One month after treatment, visual acuity improved to 20/40, with improvement of macular edema on photography (d) and OCT (e, f). Four months after treatment, visual acuity improved to 20/20, with further improvement of macular edema on photography (g) and OCT (h, i).](EDR2007-52487.001){#F1}

![Intravitreal bevacizumab for proliferative diabetic retinopathy. A patient presented with proliferative diabetic retinopathy. Fundus photography (a) and fluorescein angiography (b) are shown. The patient was treated with intravitreal bevacizumab. Followup fluorescein angiography demonstrated improvement in angiographic leakage (c). Panretinal photocoagulation was then applied (d). (Case courtesy of Geeta Lalwani, MD, and Carmen A. Puliafito, MD, MBA.)](EDR2007-52487.002){#F2}

###### 

Selected published clinical series evaluating pharmacotherapies for advanced diabetic retinopathy. CMT: central macular thickness (assessed by optical coherence tomography), FA: fluorescein angiography, IVTA: intravitreal triamcinolone acetonide, DME: diabetic macular edema, NV: neovascularization, PDR: proliferative diabetic retinopathy, TA: triamcinolone acetonide, VA: visual acuity, and VH: vitreous hemorrhage.

  -------------------------------- ------------------- --------------- -------------------------------- ---------------------------------- --------------------
  Study (reference)                Reported patients   Reported eyes   Medication                       Indication and outcome measures    Efficacy
                                                                                                                                           
  Martidis et al. \[[@B9]\]        16                  16              IVTA                             DME, VA, CMT                       Favorable
  Gillies et al. \[[@B12]\]        43                  69              IVTA                             DME, VA                            Favorable
  Lam et al. \[[@B13]\]            63                  63              IVTA                             DME, VA, CMT                       Favorable
  Tunc et al. \[[@B23]\]           50                  60              Peribulbar TA                    DME, VA, FA                        Favorable
  Bakri et al. \[[@B24]\]          50                  63              Peribulbar TA                    DME, VA                            Favorable
  Cardillo et al. \[[@B25]\]       12                  24              Peribulbar TA                    DME, VA, CMT                       Unfavorable
  Bonini-Filho et al. \[[@B26]\]   36                  36              Peribulbar TA                    DME, VA, CMT                       Unfavorable
  Kuppermann et al. \[[@B29]\]     286                 286             Extended-release dexamethasone   DME, VA, CMT                       Favorable
  Cunningham et al. \[[@B36]\]     172                 172             Pegaptanib                       DME, VA, CMT, photocoagulation     Favorable
  Adamis et al. \[[@B37]\]         16                  20              Pegaptanib                       PDR, retinal NV                    Favorable
  Spaide et al. \[[@B38]\]         2                   2               Bevacizumab                      PDR, retinal NV, VH                Favorable
  Jorge et al. \[[@B39]\]          15                  15              Bevacizumab                      PDR, VA, retinal NV, FA            Favorable
  Avery et al. \[[@B40]\]          32                  45              Bevacizumab                      PDR, VA, iris and retinal NV, FA   Favorable
  Chun et al. \[[@B41]\]           10                  10              Ranibizumab                      DME, VA, CMT                       Favorable
  Nguyen et al. \[[@B42]\]         10                  10              Ranibizumab                      DME, VA, CMT                       Favorable
  PKC-DRS \[[@B43]\]               252                 504             Ruboxistaurin                    DME, PDR, VA, Photocoagulation     Favorable
  PKC-DRS2 \[[@B44]\]              685                 1370            Ruboxistaurin                    DME, VA, Photocoagulation          Favorable
  PKC-DMES \[[@B45]\]              686                 1372            Ruboxistaurin                    DME, Photocoagulation              Unfavorable
  Strom et al. \[[@B46]\]          41                  55              Ruboxistaurin                    DME, VA, vitreous fluorometry      Somewhat favorable
  Kuppermann et al. \[[@B47]\]     1125                1125            Hyaluronidase                    VH, anatomic clearance, VA         Favorable
  DRCR.net et al. \[[@B48]\]       109                 129             Peribulbar TA                    DME, VA, CMT                       Unfavorable
  -------------------------------- ------------------- --------------- -------------------------------- ---------------------------------- --------------------

###### 

Selected ongoing clinical trials evaluating pharmacotherapies for advanced diabetic retinopathy. DME: diabetic macular edema, DRCR.net: Diabetic Retinopathy Clinical Research network, PF/IVTA: preservative-free intravitreal triamcinolone acetonide, PDR: proliferative diabetic retinopathy, and TA: triamcinolone acetonide.

  -------------------- -------------------------------- ----------------- ----------------------
  Sponsor              Medication                       Indication        Status
                                                                          
  DRCR.net (phase 3)   PF/IVTA                          DME               Completed enrollment
  Bausch & Lomb        Fluocinolone implant             DME               Completed enrollment
  Allergan (phase 3)   Extended-release dexamethasone   DME               In planning stages
  OSI/Eyetech          Pegaptanib                       DME               Enrolling patients
  DRCR.net (phase 2)   Bevacizumab                      DME               Completed enrollment
  Genentech            Ranibizumab                      DME               Enrolling patients
  DRCR.net (phase 3)   Ranibizumab or IVTA              DME with no PDR   Enrolling patients
  DRCR.net (phase 3)   Ranibizumab or IVTA              DME with PDR      Enrolling patients
  -------------------- -------------------------------- ----------------- ----------------------

###### 

Guidelines for pharmacologic treatment of advanced diabetic retinopathy.

A.  Clinically significant macular edema (CSME)

    1.  Evaluation

        a.  Initial diagnosis

            i.  Complete eye examination

            ii. Fundus photography, fluorescein angiography, optical coherence tomography (OCT)

        b.  Followup

            i.  Clinical examination

            ii. OCT

    2.  Treatment

        a.  First-line therapy

            i.  Focal or modified ETDRS grid photocoagulation for focal or diffuse CSME

            ii. Intravitreal pharmacotherapies ± photocoagulation for more advanced, diffuse CSME

        b.  For persistent or recurrent CSME (visual acuity \<20/40)

            i.  Repeat photocoagulation

            ii. Intravitreal triamcinolone acetonide or intravitreal antivascular endothelial growth factor (VEGF) agent

        c.  For CSME refractory to photocoagulation and intravitreal pharmacotherapies, consider pars plana vitrectomy (PPV)

            i.  No traction: PPV with internal limiting membrane (ILM) peeling

            ii. Taut posterior hyaloid face or vitreomacular traction syndrome: PPV and ILM peeling

B.  Proliferative diabetic retinopathy (PDR)

    1.  Evaluation

        a.  Initial diagnosis

            i.  Complete eye examination

            ii. Fundus photography, fluorescein angiography (sometimes), optical coherence tomography (OCT), echography (if necessary)

        b.  Followup

            i.  Clinical examination

            ii. OCT for evaluation of macular disease

    2.  Treatment

        a.  First-line therapy

            i.  In eyes with clear media: panretinal photocoagulation (PRP)

            ii. In eyes with vitreous hemorrhage and no retinal detachment: consider intravitreal anti-VEGF agent, with PRP after clearing

            iii. In eyes with traction retinal detachment, consider intravitreal anti-VEGF agent before pars plana vitrectomy to reduce vascularity

            iv. In eyes with attached posterior hyaloid, consider use of intravitreal triamcinolone acetonide to assist in hyaloid removal

        b.  For combined PDR/CSME

            i.  Consider medical options

                1.  Intravitreal anti-VEGF agent or hyaluronidase for vitreous hemorrhage

                2.  Standard focal or modified grid and PRP

            ii. Consider standard surgical options for more advanced disease

                1.  Nonclearing vitreous hemorrhage

                2.  Advanced traction retinal detachment
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